José Luis Monereo Pérez
YOU?
Author Swipe
View article: THE RIGHT TO COMPREHENSIVE MANAGEMENT OF WORKPLACE RISKS AND ITS LEGAL REGULATION INSTRUMENTS IN THE ERA OF DIGITALIZATION
THE RIGHT TO COMPREHENSIVE MANAGEMENT OF WORKPLACE RISKS AND ITS LEGAL REGULATION INSTRUMENTS IN THE ERA OF DIGITALIZATION Open
I. The Great Transformation of our time. 1. The Great Transformation and the prevention
View article: Supplementary Figure 2 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 2 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 208K, PI3K blockade suppresses BRCA1/2 transcription
View article: Supplementary Figure Legends 1-6, Table Legend 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure Legends 1-6, Table Legend 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 58K
View article: Data from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Data from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that in BRCA-proficient trip…
View article: Supplementary Figure 6 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 6 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 190K, ERK and ETS1 downregulate BRCA1/2 expression
View article: Supplementary Figure Legends 1-6, Table Legend 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure Legends 1-6, Table Legend 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 58K
View article: Supplementary Figure 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 195K, PI3K regulates BRCA expression
View article: Supplementary Table 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Table 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 139K, Common BRCA1 and BRCA2 promoter putative transcription factors analysis
View article: Supplementary Figure 5 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 5 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 162K, Western blot of cell lysates from MDA-MB-468 or PDC44 cells treated with 750nM and 500nM BKM120 respectively for 4 days using the indicated antibodies
View article: Supplementary Figure 4 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 4 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 3.4MB, Concordance in ER, PR, HER2, and PTEN expression between original patient tumors and the derived tumor grafts
View article: Supplementary Figure 3 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 3 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 301K, Combined PIK3CA siRNA and PARP suppression in TNBC cell lines
View article: Data from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Data from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that in BRCA-proficient trip…
View article: Supplementary Table 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Table 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 139K, Common BRCA1 and BRCA2 promoter putative transcription factors analysis
View article: Supplementary Figure 5 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 5 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 162K, Western blot of cell lysates from MDA-MB-468 or PDC44 cells treated with 750nM and 500nM BKM120 respectively for 4 days using the indicated antibodies
View article: Supplementary Figure 2 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 2 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 208K, PI3K blockade suppresses BRCA1/2 transcription
View article: Supplementary Figure 4 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 4 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 3.4MB, Concordance in ER, PR, HER2, and PTEN expression between original patient tumors and the derived tumor grafts
View article: Supplementary Figure 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 195K, PI3K regulates BRCA expression
View article: Supplementary Figure 6 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 6 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 190K, ERK and ETS1 downregulate BRCA1/2 expression
View article: Supplementary Figure 3 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Supplementary Figure 3 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition Open
PDF file - 301K, Combined PIK3CA siRNA and PARP suppression in TNBC cell lines
View article: Supplementary Figure 8 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 8 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 281KB, Trastuzumab treatment in trastuzumab-resistant patient derived-xenografts.
View article: Supplementary Figure 6 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 6 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 233KB, In vitro cell death induced by lapatinib and INK-128 of trastuzumab/lapatinib resistant cell lines.
View article: Supplementary Figure 1 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 1 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 760KB, Biochemical analyses of trastuzumab/lapatinib sensitive cells treated with lapatinib.
View article: Supplementary Figure 5 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 5 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 593KB, In vitro cell death induced by lapatinib and INK-128 of trastuzumab/lapatinib resistant cell lines.
View article: Supplementary Figure 4 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 4 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 523KB, Cell cycle analysis of trastuzumab/lapatinib resistant cells.
View article: Supplementary Figure 5 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 5 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 593KB, In vitro cell death induced by lapatinib and INK-128 of trastuzumab/lapatinib resistant cell lines.
View article: Supplementary Figure 1 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 1 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 760KB, Biochemical analyses of trastuzumab/lapatinib sensitive cells treated with lapatinib.
View article: Supplementary Figure 7 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 7 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 386KB, In vivo treatments of JIMT1 xenografts.
View article: Supplementary Figure 3 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Supplementary Figure 3 from Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy Open
PDF file, 714KB, Combination index (CI) of the combination of lapatinib and INK-128 in resistant cell lines.